Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Boston Scientific stock gains pipeline support after Q3 report

Clinical trial results Device clearance New AI features AI-generated analysis

πŸ“ˆ Boston Scientific achieved third-quarter net sales of USD 5.138 billion, marking a 1.5% increase on reported, operational, and organic bases.

πŸ’Š The company initiated enrollment in the Elite AF trial for its next-generation WATCHMAN Elite left atrial appendage closure device.

βœ… Boston Scientific received FDA 510(k) clearance for the Navigator Flex Ureteral Access Sheath Set and the LithoVue Elite single-use digital flexible ureteroscope.

πŸ”§ The firm secured further FDA clearance for an expanded size range of its SEISMIQ intravascular lithotripsy peripheral catheter.

🀝 Boston Scientific highlighted a collaboration with Heartflow to advance artificial-intelligence-supported computed tomography planning for percutaneous coronary intervention.

⚠️ Management expects fourth-quarter reported and organic sales to decline between 1.0% and 3.0% year over year due to cybersecurity disruptions.

πŸ“… Full-year 2026 guidance forecasts reported sales growth of 4.25% and organic growth of 3.75%.

Bullish Signals
  • Boston Scientific achieved third-quarter net sales of USD 5.138 billion, representing a 1.5% increase on reported, operational, and organic bases.
  • The company initiated enrollment in the Elite AF clinical trial for its next-generation WATCHMAN Elite device, advancing its pipeline in left atrial appendage closure.
  • Boston Scientific received FDA 510(k) clearance for the Navigator Flex Ureteral Access Sheath Set and the LithoVue Elite single-use digital flexible ureteroscope with temperature sensing.
  • The firm secured further FDA clearance for an expanded size range of its SEISMIQ intravascular lithotripsy peripheral catheter, broadening its product portfolio.
  • Boston Scientific highlighted a strategic collaboration with Heartflow to advance artificial-intelligence-supported computed tomography planning for percutaneous coronary intervention.
Risk Factors
  • Management expects fourth-quarter reported and organic sales to decline between 1.0% and 3.0% year over year due to ongoing cybersecurity disruptions affecting operations.
  • The company faces near-term revenue pressure as it navigates operational challenges stemming from the cybersecurity incident.
Full Analysis
Boston Scientific reported third-quarter net sales of USD 5.138 billion, representing a 1.5% increase on reported, operational, and organic bases compared to the prior year. The company delivered adjusted earnings per share of USD 0.73 and GAAP earnings per share of USD 0.40, contrasting with the previous year's figures of USD 0.51 for GAAP EPS. The medical technology firm announced several significant pipeline milestones alongside its financial results. Key developments include the initiation of enrollment in the Elite AF clinical trial for its next-generation WATCHMAN Elite device and receiving FDA 510(k) clearances for the Navigator Flex Ureteral Access Sheath Set, the LithoVue Elite ureteroscope, and an expanded size range for its SEISMIQ intravascular lithotripsy peripheral catheter. Looking ahead, management issued a weaker near-term sales outlook due to ongoing cybersecurity disruptions affecting operations. The company expects fourth-quarter reported and organic sales to decline between 1.0% and 3.0% year over year. Full-year 2026 guidance projects reported sales growth of 4.25% and organic growth of 3.75%, with adjusted earnings per share forecasted between USD 3.16 and USD 3.18.